Lung cancer is a cancer that originates in the cells of the lung. It is one of the most common cancers worldwide and a leading cause of cancer-related death. Alfa Cytology is a global leader in cancer research. With extensive experience and advanced platforms, our talented scientists provide solutions covering animal model development, efficacy evaluation, orthotopic lung model validation, organ-specific metastasis research, tumor immunology testing, target expression validation, pathology testing, molecular mechanism testing, and PK/PD studies, tailored to client candidate drugs, target types, lung cancer subtypes, cell line molecular profiles, immune system requirements, metastatic organ scenarios, and R&D stages. In addition, we offer zebrafish experimental services and cell-based experimental services to support diverse research needs, from in vitro to in vivo, and from high-throughput screening to mechanism validation.
Introduction to Lung Cancer
Lung cancer is mainly divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Smoking is the leading cause of lung cancer, although non-smokers may also develop the disease. Prevention and early detection are key to lung cancer control. In 2024, an estimated 234,580 new lung cancer cases and 125,070 deaths were reported in the United States. Treatment options for lung cancer include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and combinations of these modalities. The choice of treatment depends primarily on cancer stage or severity, but other factors are also important, such as the patient's overall health and lung function, as well as certain characteristics of the cancer itself.
Fig.1 The therapies for lung cancer. (Ashrafi, A., et al., 2022)
With long-term research into disease targets and the immune system, targeted therapy and immunotherapy, characterized by precision and reduced side effects, have emerged as novel therapeutic approaches following surgery, chemotherapy, and radiotherapy. Several pharmaceutical companies and their lung cancer drug development programs are highlighted below.
| Targets |
Therapeutics |
Company |
Molecule Type |
Phase |
| PD-1 |
MK-3475 |
Merck |
Monoclonal antibody |
|
| B7-H3 IgG1 |
Ifinatamab deruxtecan (MK-2400) |
Merck |
Antibody-drug conjugate |
|
| SEZ6 |
ABBV-706 |
Abbvie |
Antibody-drug conjugate |
|
| TIGIT |
Tiragolumab |
Genentech |
Monoclonal antibody |
|
Our Services
Alfa Cytology has established a comprehensive solution platform for lung cancer animal experimental research, built around SCLC lineage stratification, NSCLC driver gene stratification, orthotopic lung microenvironment, brain/bone/liver organ-specific metastasis, immunotherapy, humanized immunotherapy, and resistance/relapse scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full lung cancer research workflow.
Preclinical Efficacy Studies
Lung cancer drug development requires model selection based on subtype, driver gene, target expression, immune requirements, and metastatic organ scenarios. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for chemotherapy, small molecule targeted therapies, EGFR-TKIs, KRAS/MET/HER2 agents, ADCs, bispecifics, T-cell engagers (TCEs), CAR-T/NK, PD-1/PD-L1, STING, radiotherapy combination, local delivery, and resistance/relapse programs.
Lung Cancer Mechanism Research
For lung cancer studies, experimental design typically needs to address cell line stratification, driver genes, lung microenvironment, metastatic organs, and immune microenvironment simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering SCLC lineage, NSCLC driver genes, brain metastasis, bone metastasis, systemic dissemination, TME, resistance/relapse, and combination therapy mechanisms.
Candidate Screening
Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, and target pathway evaluations using molecularly matched subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.
Clinical Relevance Studies
When programs advance to orthotopic lung, brain metastasis, bone metastasis, immunotherapy, humanized immunotherapy, local delivery, or resistance/relapse stages, Alfa Cytology can further configure orthotopic models, metastasis models, syngeneic immunocompetent models, or humanized immune models to help clients generate evidence more aligned with clinical scenarios.
In Vitro and In Vivo Layered Validation
Animal studies can address whether a candidate inhibits tumor growth, intrapulmonary burden, organ metastasis, or immune evasion; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, metastatic invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, target expression, drug internalization, resistance mechanisms, and immune killing.
Molecular Mechanism Studies
Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, target expression validation, tumor immune profiling, PK/PD, tumor tissue drug concentration, brain tissue exposure, and lung tissue exposure testing.
For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation,translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:
Supported R&D Programs
|
R&D Project
|
Cell Lines
|
Host System
|
Preferred Model
|
Key Endpoints
|
|
SCLC early efficacy screening
|
H69, H209, DMS53, H82, H446, H146
|
BALB/c nude, NOD-SCID, NSG
|
SCLC subcutaneous CDX
|
TGI, RTV, terminal tumor weight, Ki67, cleaved caspase-3, INSM1, ASCL1, synaptophysin.
|
|
SCLC DLL3 / TCE programs
|
H69, H209, DMS53 (ASCL1-related)
|
huPBMC or huHSC system
|
DLL3-high SCLC CDX, escalation to humanized models when needed
|
DLL3 expression, TGI, T cell infiltration, Granzyme B, IFN-γ, CRS risk markers.
|
|
SCLC resistance & relapse
|
H69AR, H82, H446, resistant derivatives
|
NOD-SCID, NSG
|
Resistant CDX or systemic dissemination model
|
TGI, resistance markers, DNA damage response, BCL2, topoisomerase-related markers, survival.
|
|
NSCLC EGFR-sensitive mutation
|
PC9, HCC827
|
BALB/c nude, NSG
|
EGFR-stratified subcutaneous CDX, with orthotopic validation when needed
|
TGI, pEGFR, pERK, pAKT, Ki67, apoptosis, plasma ctDNA, PK/PD.
|
|
NSCLC EGFR-resistant background
|
H1975, H1975-luc
|
BALB/c nude, NSG
|
H1975 CDX or H1975-luc orthotopic/brain metastasis model
|
TGI, pEGFR, pERK, resistance markers, ADC targets, intracranial tumor burden.
|
|
KRAS / MET / p53 / invasion
|
A549, H23, H358, H1993, H1299
|
N/A
|
Molecularly matched CDX, with orthotopic or metastasis model validation
|
TGI, pERK, pMET, EMT, invasion and metastasis markers, intrapulmonary burden.
|
|
Lung orthotopic microenvironment
|
PC9-luc, H1975-luc, A549-luc, H1299-luc, SCLC luc-labeled lines
|
N/A
|
Orthotopic lung model
|
BLI, micro-CT, lung histopathology, local invasion, mediastinal lymph nodes, survival.
|
|
NSCLC brain metastasis
|
H2030-BrM, PC9-BrM, H1975-BrM, PC9-luc, H1975-luc
|
N/A
|
Left ventricle / carotid artery injection or intracranial inoculation
|
MRI/BLI, brain metastatic burden, survival, neurobehavior, brain edema, brain histopathology.
|
|
NSCLC bone metastasis
|
HARA-B, H1299, A549 bone-tropic derivatives
|
N/A
|
Left ventricle injection or tibial/femoral inoculation
|
micro-CT, X-ray, bone destruction score, bone pain behavior, survival, bone histopathology.
|
|
SCLC systemic dissemination / liver metastasis
|
H82, H69, H446
|
NOD-SCID, NSG
|
Tail vein, portal vein, or intrasplenic injection
|
BLI, liver metastatic nodules, liver weight, liver histopathology, INSM1, ASCL1, synaptophysin, survival.
|
|
Immunotherapy / TME research
|
LLC1, LLC1-luc, CMT167, KLN205
|
C57BL/6, DBA/2
|
Syngeneic immunocompetent subcutaneous or orthotopic model; orthotopic preferred
|
TGI/BLI, survival, CD8/Treg, myeloid cell profile, BALF composition, PD-L1, cytokines.
|
|
Human immune-dependent therapies
|
Human lung cancer cell lines
|
huPBMC or huHSC
|
Humanized immune model
|
hCD45, hCD3, hCD8, T cell activation, cytokines, tumor burden, xGvHD/CRS risk.
|
|
Local delivery / lung-penetrating drug evaluation
|
NSCLC-luc or SCLC-luc orthotopic lines
|
N/A
|
Orthotopic lung model or local pulmonary delivery model
|
Intrapulmonary exposure, lung tissue concentration, BLI, local toxicity, lung pathology, BALF inflammation.
|
Comprehensive Test and Data Analysis Platform
We flexibly configure endpoints to meet project objectives. Options include TGI, RTV, terminal tumor weight, BLI, micro-CT, MRI, survival, brain metastases, bone destruction scores, liver metastatic nodules, pulmonary tumor burden, mediastinal lymph nodes, Ki67, cleaved caspase-3, pEGFR, pERK, pMET, INSM1, ASCL1, synaptophysin, DLL3, TROP2, HER3, HER2, CD8/Treg, myeloid cell profiling, cytokines, plasma drug concentration, tumor tissue concentration, and brain/bone/lung tissue exposure. This delivers comprehensive characterization across in vivo imaging, quantitative pathology, TME immune phenotyping, and PK/PD exposure.
Multimodal In Vivo Imaging
- IVIS spectrum photon bioluminescence quantification.
- 7.0T small-animal high-field MRI for intracranial lesion scanning.
- micro-CT 3D reconstruction of osteolysis and bone mineral density.
Pathology and IHC/IF Staining
- pEGFR / pERK / DLL3 target phosphorylation assessment.
- Ki67 / Cleaved-Caspase 3 apoptosis index.
- mIF multiplex immunofluorescence for in situ target and TME quantification.
TME Microenvironment and Immune Profiling
- TILs (CD4+ / CD8+ / Treg) infiltration ratio analysis.
- TAM (M1 / M2) and MDSC suppressive subsets.
- Cytokine storm (IFN-γ / IL-6) CBA suspension array.
Access Our Lung Cancer Model Library
Lung Cancer Cell Line Panel
Alfa Cytology's lung cancer cell line panel covers five key areas, including SCLC, NSCLC, metastasis research, immuno-oncology, and target expression, enabling cell line selection and matching based on molecular background, driver gene, target status, and immune system requirements.
- ASCL1-related cell lines: H69, H209, and DMS53 are suitable as ASCL1-related SCLC models, applicable to studies on classical neuroendocrine features, DLL3, BCL2, INSM1, synaptophysin, sensitivity to standard chemotherapy, and first-line treatment strategies.
- NEUROD1-preferring cell lines: H82, H446, and H146 are suitable for research on NEUROD1 preference, high proliferation, variant phenotype, invasion, and drug resistance. Compared with H69/H209, these models are better suited to addressing whether a candidate drug covers more difficult-to-treat variant phenotypes or resistance directions.
- POU2F3-related cell lines: H1048 and H211 are applicable to POU2F3-related, low-neuroendocrine-feature, or atypical SCLC research. If the project focuses on lineage plasticity, low-NE status, or subtype switching, validation in parallel with ASCL1 or NEUROD1 representative lines should be considered.
- Drug-resistant cell lines: H69AR can be used for extended studies on platinum-based or multidrug resistance, suitable for later-line treatment, resistance mechanisms, drug efflux, DNA damage response, and combination therapy strategies.
- EGFR-sensitizing mutation cell lines: PC9 and HCC827 represent EGFR-sensitizing mutation NSCLC, suitable for EGFR-TKI, EGFR-related bispecific antibodies, ADCs, combination therapy, and pre-resistance strategies. Osimertinib, EGFR bispecific antibody, or combination therapy projects should prioritize these cell models.
- EGFR-resistant background cell lines: H1975 represents the EGFR L858R/T790M resistance background, suitable for EGFR later-line strategies, resistance mechanisms, ADCs, bispecific antibodies, and combination therapy research.
- RAS pathway-related cell linesK: A549, H23, and H358 are commonly used for KRAS pathway, chemotherapy, metabolism, EMT, and combination therapy basic research. EGFR-sensitive models should not be used as substitutes for KRAS projects, especially when evaluating KRAS pathway inhibition, immune combination, or metabolic reprogramming.
- MET pathway cell lines: H1993 is suitable for MET high-expression or MET pathway-related research, and can be used for MET inhibitors, MET ADCs, MET-related bispecific antibodies, and resistance mechanism projects.
- p53-null and invasive cell lines: H1299 is more suitable for p53 deletion, invasion, migration, EMT, orthotopic lung invasion, and pre-bone metastasis research. For projects emphasizing metastatic capacity or tumor invasiveness, H1299 is more appropriate than purely low-invasive or growth-oriented models.
Metastasis Research Cell Lines
- Brain metastasis research cell lines: For NSCLC brain metastasis projects, models such as H2030-BrM, PC9-BrM, H1975-BrM, PC9-luc, and H1975-luc can be selected. If the project focus is BBB penetration, left ventricular or carotid artery injection to form brain metastasis should be prioritized; if the focus is intracranial killing and brain tissue exposure, intracranial inoculation can be selected.
- Bone metastasis research cell lines: For bone metastasis projects, HARA-B, H1299, and A549 bone-tropic derivatives can be considered. If the project emphasizes bone destruction, bone pain, and bone microenvironment, micro-CT, bone pathology, and pain behavioral endpoints should be configured.
- SCLC liver metastasis and systemic dissemination research cell lines: H82, H69, and H446 are suitable for systemic dissemination, liver colonization, and later-line treatment research. If the project focuses on rapid SCLC dissemination and recurrence, models with dissemination propensity or BLI monitoring capability should be prioritized.
Immunological Research Cell Lines
- Human lung cancer cell lines: Human lung cancer cell lines such as PC9, H1975, and A549 are suitable for immunodeficient CDX systems. This system is suitable for chemotherapy, small molecules, some ADCs, and non-immune-dependent drug screening, but cannot address questions regarding complete T cells, myeloid cells, PD-1/PD-L1, STING, and TME remodeling.
- LLC1 / LLC1-luc: LLC1 and LLC1-luc are C57BL/6 background syngeneic lung cancer cell lines that retain the host immune system, suitable for immunotherapy, radiotherapy combination, STING, cytokines, oncolytic viruses, and TME mechanism research.
- CMT167: CMT167 is a C57BL/6 background syngeneic lung cancer cell line that is relatively more sensitive to PD-1/PD-L1 inhibition, suitable for immunotherapy and orthotopic lung immune microenvironment research.
- KLN205: KLN205 is a DBA/2 background syngeneic lung cancer cell line, suitable for squamous cell carcinoma-related syngeneic model research.
- Human lung cancer cell lines + huPBMC / huHSC: For TCE, CAR-T/NK, human immune checkpoint, human cytokine, and human immune cell-dependent drug projects, human lung cancer cell lines combined with huPBMC or huHSC humanized models need to be considered. huPBMC is suitable for short-cycle effector validation, while huHSC is suitable for longer-cycle and complex immune mechanism research.
Target Expression-Related Cell Lines
- DLL3: For DLL3-directed projects, ASCL1-related SCLC cell lines with stable DLL3 expression, such as H69, H209, or DMS53, should be prioritized. For TCE or DLL3 ADC projects, DLL3 expression retention should be confirmed in vitro, after tumor formation, and at the endpoint stage whenever possible.
- EGFR: For EGFR-sensitizing mutation projects, select PC9 or HCC827; for EGFR-resistant projects, select H1975 or corresponding resistant derivative models. EGFR projects should simultaneously detect pEGFR, pERK, pAKT, and downstream pathway inhibition.
- MET: For MET projects, MET high-expression models such as H1993 can be selected, and MET expression and pathway activity should be detected before and after treatment. If the project is a MET ADC, cell surface expression and tissue target retention also need to be verified.
- TROP2 / HER3 / HER2 / EGFR Ex20ins: For ADC, bispecific antibody, and novel target projects, target expression stability should be confirmed first and should be consistent with the clinical indication.
Lung Cancer Animal Model Panel
Alfa Cytology provides end-to-end lung cancer animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across SCLC and NSCLC research. Each model can be customized to match your program's subtype, driver gene, target expression, immune requirements, and metastatic organ scenario. from early screening to clinical relevance validation.
Subcutaneous Xenograft Model (CDX)
Subcutaneous CDX models typically involve inoculating human SCLC or NSCLC cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume.
- SCLC cell lines: H69, H209, DMS53, H82, H446, H146, H69AR.
- NSCLC cell lines: PC9, HCC827, H1975, A549, H23, H358, H1993, H1299.
Model characteristics
Subcutaneous CDX is suitable for early efficacy studies, target validation (e.g., EGFR, KRAS, MET, DLL3, HER3, TROP2, HER2), dose exploration, PK/PD studies, and resistance and combination therapy research. However, this model cannot fully reflect the orthotopic lung microenvironment, lung tissue exposure, brain/bone metastasis, mediastinal lymph nodes, or intact immune responses.
Modeling and dosing timelines
Palpable tumor volumes suitable for enrollment are typically reached 1–3 weeks after inoculation, and stratified randomization by tumor volume is recommended. The conventional treatment observation period is usually 2–4 weeks; for special projects (resistance, sustained-release formulations, ADCs, or antibody drugs), this can be extended according to pharmacokinetic and toxicity windows. For resistance, recurrence, or sustained suppression studies, a post-treatment withdrawal observation period can be added to record tumor regrowth and regrowth rate.
Detection endpoints
- Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival.
- Molecular mechanism layer: Ki67, cleaved caspase-3, TUNEL, pEGFR, pERK, pAKT, pMET, INSM1, ASCL1, synaptophysin, DLL3, TROP2, HER3, HER2, and DNA damage markers.
- PK/PD layer: Plasma drug concentration, tumor tissue concentration, target occupancy, pathway inhibition, and ADC tissue distribution.
- Safety layer: Body weight, complete blood count, liver and kidney function, and major organ pathology.
Recommended positive controls
For SCLC, Cisplatin (2–5 mg/kg i.p./i.v.), Etoposide (5–10 mg/kg i.p./i.v.), or Carboplatin/Topotecan can be selected; for NSCLC EGFR, Osimertinib (5–25 mg/kg p.o., QD) can be used; MET or ADC projects require matching positive controls.
Orthotopic lung models typically involve placing tumor cells into the lung organ environment via intrathoracic injection, lung parenchymal injection, endobronchial implantation, or targeted inoculation on the lung lobe surface, often using luc-labeled cells for dynamic monitoring.
- SCLC orthotopic models: H69, H187, N417, etc., suitable for orthotopic lung invasion, local drug delivery, and systemic dissemination studies, and better suited for investigating intrapulmonary growth, dissemination, and local microenvironmental influences.
- NSCLC orthotopic models: PC9-luc, H1975-luc, A549-luc, H1299-luc, suitable for lung organ microenvironment, local invasion, hilar or mediastinal lymph node metastasis, and evaluation of local formulations or lung tissue-penetrating drugs.
Model characteristics
Suitable for lung organ microenvironment, intrapulmonary efficacy, local invasion, local drug delivery, and pre-metastatic research. However, orthotopic lung models have low throughput, complex procedures, and high inter-batch variability, and are not suitable as the highest-throughput early screening platform. Early screening can first use subcutaneous CDX, followed by orthotopic validation.
Modeling and dosing timelines
Orthotopic models are typically observed for 3–6 weeks, depending on the cell line, inoculation method, and tumor growth rate. Luc-labeled models can be longitudinally monitored by BLI. The treatment window is usually 2–6 weeks; targeted agents, chemotherapy, ADCs, and local drug delivery can be designed according to model burden and pharmacokinetic windows. Treatment can begin after BLI confirms tumor establishment, or intervention can be timed according to local invasion or metastatic windows, but dosing should not be too late, as excessive tumor burden may compromise survival and detection windows.
Detection endpoints
- Tumor burden layer: BLI, micro-CT, intrapulmonary nodules, lung weight, tumor area, intrapulmonary pathology, and survival.
- Local invasion layer: Alveolar, interstitial, and vascular interfaces, pleural involvement, hilar or mediastinal lymph node metastasis, and local vascular invasion.
- Lung microenvironment layer: BALF cell composition, local inflammatory cytokines, immune cell infiltration, angiogenesis, fibrosis, and lung tissue injury.
- Drug exposure layer: Plasma drug concentration, lung tissue drug concentration, tumor tissue concentration, BALF drug exposure, and local toxicity.
Recommended positive controls
For EGFR models, Osimertinib can be used as an EGFR-TKI reference (oral daily dosing for 2–4 weeks, with pEGFR and downstream pathway detection); for chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Gemcitabine, or Pemetrexed can be selected, and for SCLC, platinum-based combination with etoposide can be referenced; for local drug delivery projects, systemic dosing controls and local dosing controls can be set up, focusing on comparing lung tissue exposure, intrapulmonary efficacy, and local safety.
Organ-Specific Metastasis Models
Organ-specific metastasis models involve injecting tumor cells via tail vein, portal vein, intrasplenic, left ventricular, carotid artery, or intraosseous routes to colonize specific organs, used to study metastatic colonization, organ microenvironment, and brain/bone/liver metastasis scenarios.
- SCLC systemic dissemination and liver metastasis models: H82, H69, H446, etc., established via tail vein, portal vein, or intrasplenic injection, suitable for studying rapid SCLC dissemination, organ colonization, and later-line treatment.
- SCLC brain metastasis and intracranial models: Established via left ventricular, carotid artery injection, or direct intracranial inoculation; left ventricular or carotid artery models are more suitable for studying BBB penetration and brain colonization, while intracranial models are more suitable for intracranial efficacy and brain tissue exposure studies.
- NSCLC brain metastasis models: H2030-BrM, PC9-BrM, H1975-BrM, PC9-luc, H1975-luc are used for brain metastasis research; left ventricular injection is more suitable for brain colonization, carotid artery injection can increase brain burden, and intracranial inoculation is more suitable for intracranial efficacy and drug exposure evaluation.
- NSCLC bone metastasis models: HARA-B, H1299, and A549 bone-tropic derivatives can be used for bone metastasis research; left ventricular injection is suitable for bone colonization and systemic dissemination, while tibial or femoral injection is suitable for local bone microenvironment and bone destruction studies.
- Model characteristics: These models are suitable for organ colonization, post-metastasis treatment, BBB penetration, bone microenvironment, and bone destruction research.
Modeling and dosing timelines
The observation period for brain metastasis models is typically 2–8 weeks, and the treatment window should be determined based on BLI or MRI signals; delayed dosing may affect endpoints due to neurological symptoms. Systemic dissemination and bone metastasis models require dosing schedules designed according to model windows and animal tolerance.
Detection endpoints
- SCLC systemic dissemination/liver metastasis: BLI, number of liver metastatic nodules, liver weight, liver tissue HE, INSM1, ASCL1, synaptophysin, Ki67, survival, and liver function.
- SCLC brain metastasis: BLI/MRI, intracranial tumor burden, survival, neurobehavior, brain edema, brain tissue pathology, and brain tissue drug concentration.
- NSCLC brain metastasis: MRI/BLI, survival, number of brain metastases, brain edema, neurobehavioral scoring, brain tissue HE, Ki67, apoptosis, BBB-related markers, and brain tissue drug concentration.
- NSCLC bone metastasis: micro-CT, X-ray, bone destruction score, bone density, TRAP staining, bone tissue pathology, bone pain behavior, survival, and bone-related factors.
Recommended positive controls
For SCLC systemic dissemination/liver metastasis, platinum-based combination with etoposide can be used as a first-line reference, and Topotecan, Lurbinectedin, or DLL3-directed agents can be used as later-line or mechanistic references; for EGFR-mutant brain metastasis projects, Osimertinib can be set as a reference; ADC or bispecific antibody projects should be designed based on target expression and intracranial exposure; radiotherapy combination projects can include local irradiation controls.
Syngeneic Immunocompetent Models
Syngeneic immunocompetent models retain the host immune system and are suitable for immunotherapy, radiotherapy combination, STING, cytokines, oncolytic viruses, and TME mechanism research.
- NSCLC syngeneic models: LLC1, LLC1-luc, CMT167 are used in the C57BL/6 background, and KLN205 can be used in the DBA/2 background; models can be established subcutaneously or orthotopically in the lung. If the project focus is immunotherapy and TME research, orthotopic lung models have higher priority.
- SCLC immunocompetent models: These mostly rely on syngeneic transplantation models of GEMM-derived tumor cells or tumor fragments, which better preserve the immune background and lineage state than standard human SCLC CDX.
Model characteristics:
The CMT167 orthotopic model is relatively more sensitive to PD-1/PD-L1 inhibition, while LLC1 typically responds weakly; the two can be used to construct a comparison platform of immune-sensitive and relatively resistant models; KLN205 is suitable for squamous cell carcinoma-related syngeneic model research. This model retains an intact immune system and is suitable for immune checkpoint, STING, cytokine, radiotherapy combination, TME remodeling, and immune resistance research. However, SCLC immunocompetent models have higher acquisition difficulty and standardization thresholds than NSCLC syngeneic models, and are not suitable for highest-throughput screening; they can serve as key validation after CDX and dissemination models are positive.
Detection endpoints
TGI, BLI, intrapulmonary tumor burden, survival, CD8/Treg, MDSC, macrophages, DC cells, PD-L1, IFN-γ, Granzyme B, BALF cell composition, and tumor tissue immunophenotyping.
Recommended positive controls
anti-PD-1, anti-PD-L1, anti-CTLA-4 can be administered intraperitoneally at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks; STING agonists, cytokines, oncolytic viruses, or radiotherapy combinations should be individually designed according to mechanism.
Humanized immune models reconstruct the human immune environment by infusing human immune cells or human hematopoietic stem cells into immunodeficient mice, suitable for TCE, CAR-T/NK, human immune checkpoints, and human immune-dependent mechanism validation.
- huPBMC model: Established by infusing human peripheral blood mononuclear cells into immunodeficient mice to create a short-term human immune effector environment, which can be combined with human lung cancer CDX; modeling is relatively rapid and suitable for short-cycle validation.
- huHSC model: Reconstructs a relatively long-term human immune system via human hematopoietic stem cells; the cycle is longer, but it is more suitable for complex immune microenvironment, human immune cell differentiation, and long-term mechanism research.
Model characteristics
Suitable for TCE, CAR-T/NK, human immune checkpoints, immune resistance, complex combination therapy, and human immune microenvironment mechanism research. However, humanized models are costly, highly variable, and subject to significant donor differences, with risks of xGvHD or cytokine release; they are not recommended as large-scale early screening models, but are more suitable as key immune mechanism and translational validation platforms.
Detection endpoints
- huPBMC: hCD45, hCD3, hCD4, hCD8, NK cells, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, and xGvHD manifestations.
- huHSC: Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology.
Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanistic references, with doses determined by antibody half-life, model window, and human immune reconstitution status; TCE, CAR-T, or CAR-NK projects should include target-positive, target-low/negative, effector cell controls, and empty vector/irrelevant TCE controls; cell therapy doses are often designed on the order of 10^6–10^7 cells/mouse, with specifics determined by the cell product and safety window.
Drug Resistance and Recurrence Research Models
Drug resistance and recurrence research models use resistant cell lines, long-term dosing induction, withdrawal relapse observation, or recurrence models to address first-line resistance, later-line resistance, lineage switching, and re-treatment sensitivity questions.
- SCLC resistance and recurrence: H69AR, H82, H446, or treatment-induced resistant models can be used; if focusing on platinum resistance, multidrug resistance, DNA damage response, or later-line treatment, early evaluation can be completed in subcutaneous CDX, followed by escalation to dissemination or organ metastasis models.
- NSCLC resistance and recurrence: H1975 can be used for the EGFR T790M background; osimertinib-resistant projects should select corresponding cell lines or induced resistant strains based on the resistance mechanism; if studying brain metastasis resistance, H1975-luc or related brain metastasis models should be used; for EGFR-TKI later-line, ADC, HER3, TROP2, MET, or bispecific antibody combination projects, target expression, resistance mechanism, and tumor tissue exposure need to be confirmed; subcutaneous CDX can be used for early screening, and orthotopic or metastasis models for key validation.
Model characteristics
These models are suitable for resistance mechanism, combination therapy, later-line treatment, and drug combination prioritization research.
Modeling and dosing timelines
After efficacy reaches suppression, dosing can be withdrawn to observe tumor regrowth time, regrowth rate, and molecular marker changes; re-challenge with the original regimen, alternative targeted agents, ADCs, immune combinations, or chemotherapy combinations can be set up to observe sensitivity changes after recurrence.
Detection endpoints
- SCLC: TGI, regrowth rate, DNA damage markers, BCL2, TOP1, ABC transporters, neuroendocrine markers, lineage switching-related indicators, and survival.
- NSCLC: pEGFR, pERK, pAKT, MET amplification or bypass activation, EMT, target expression retention, ctDNA, tumor tissue drug concentration, and regrowth curves.
Recommended positive controls
For SCLC, Topotecan, Lurbinectedin, or DLL3-related agents can be used as later-line or mechanistic references, with specific doses designed according to model window and resistance phenotype; for NSCLC, corresponding targeted agents, ADCs, or combination regimens can be selected as references according to the resistance mechanism.
How to Select the Right Model for Your Program?
By Subtype
By Drug Type
By Research Objective
By Route of Administration
By Development Pathway
- SCLC Programs: Lineage and therapeutic objectives should be defined first. Standard chemotherapy, DLL3, neuroendocrine features, systemic dissemination, and resistance/relapse are common research themes. For early-stage studies, subcutaneous CDX models such as H69, H209, H82, and H446 can be used; for systemic dissemination, liver metastasis, or brain metastasis, escalation to organ-specific metastasis models is required; for TCE or human immune-dependent therapeutics, humanized models should be considered.
- NSCLC Programs: Driver gene stratification should be prioritized. For EGFR-sensitizing mutations, select PC9/HCC827; for EGFR resistance, select H1975; for KRAS, select A549/H23/H358; for MET, select H1993; for invasion and metastasis, select H1299. If the program involves the lung microenvironment, brain metastasis, bone metastasis, or immunotherapy, orthotopic, metastasis, or syngeneic immunocompetent models should be further selected.
- Chemotherapy and cytotoxic agents: It is recommended to start with subcutaneous CDX. For SCLC, etoposide combined with cisplatin or carboplatin can be used; for NSCLC, cisplatin, taxanes, pemetrexed, or gemcitabine can be used as references.
- Targeted therapies: EGFR, ALK, ROS1, MET, KRAS, HER2, and other targets should strictly match the cell line and driver background.
- ADCs and bispecifics: Design should focus on target expression stability, internalization, bystander effect, and tissue exposure.
- Immunotherapy: PD-1/PD-L1, STING, cytokines, oncolytic virus, and radiotherapy combination programs should preferentially use syngeneic immunocompetent models. If the program is highly dependent on the human immune system, humanized models are required.
- Cell therapy and TCE: Combine humanized models, in vitro killing assays, target validation, and cytokine release risk assessment.
- Early tumor shrinkage and dose finding: Prioritize subcutaneous CDX (TGI, RTV, tumor weight, PK/PD).
- Lung organ microenvironment: Prioritize orthotopic lung models (BLI, micro-CT, lung pathology, survival).
- Brain metastasis: Brain metastasis or intracranial inoculation models (MRI/BLI, neurobehavior, brain exposure).
- Bone metastasis: Left ventricle or intrabone inoculation (micro-CT, bone destruction score, bone pain).
- Tumor immune microenvironment: Syngeneic immunocompetent or humanized models (CD8/Treg, myeloid profile, cytokines).
- Resistance and relapse: Resistant lines / induced models / drug withdrawal relapse observation (relapse time, alternative pathways).
- Systemic administration: Oral, intraperitoneal, intravenous, and subcutaneous administration are suitable for subcutaneous CDX, orthotopic, metastasis, and immune models. Dosing frequency should be set according to pharmacokinetic profile, toxicity window, and model progression rate.
- Local pulmonary administration: Inhalation, intratracheal administration, local pulmonary delivery, or nanoparticle-based programs are better suited to orthotopic lung models or local pulmonary exposure models. Key endpoints include lung tissue concentration, BALF, local inflammation, and lung pathology safety.
- Brain metastasis administration: Brain metastasis programs should consider BBB penetration, brain tissue exposure, and intracranial efficacy. After systemic administration, brain tissue drug concentration should be measured; intracranial models are better suited for direct observation of intracranial efficacy.
- Radiotherapy combination: Radiotherapy combination is suitable for syngeneic immunocompetent models, orthotopic models, and metastasis models. Irradiation dose, fractionation schedule, dosing sequence, and immune/tissue damage endpoints should be designed according to research objectives.
- SCLC: Subcutaneous CDX early screening → orthotopic lung or dissemination model → DLL3/TCE humanized validation → immunocompetent escalation model.
- NSCLC driver gene pathway: Molecular-matched subcutaneous CDX → orthotopic lung model → brain/bone metastasis model → immune or humanized model confirmation.
- ADC/bispecific pathway: Target expression confirmation → target-positive CDX → orthotopic/metastasis validation → PK/PD and target retention verification.
- Immunotherapy pathway: Syngeneic subcutaneous early screening → syngeneic orthotopic lung validation → immune profiling → combination regimen optimization; human target programs can be further escalated to humanized immune models.
Why Alfa Cytology?
Subtype-Driven Modeling
Alfa Cytology designs tailored model pathways based on SCLC lineage features (ASCL1/NEUROD1, etc.) and NSCLC driver genes (EGFR/KRAS/MET, etc.), avoiding cross-subtype misinterpretation.
Stratified Cell Line Directory
Cell line selection directly impacts lung cancer model outcomes. Alfa Cytology helps clients match model systems such as H69, H209, H82, PC9, HCC827, H1975, A549, H1993, H1299, LLC1, and CMT167 based on lineage features, driver genes, target expression, metastatic capacity, and immune requirements.
Organ-Specific Translational Models
Subcutaneous CDX models are suitable for early screening but cannot address questions related to the orthotopic lung microenvironment, brain metastasis, bone metastasis, or local drug delivery. Alfa Cytology helps clients generate organ-specific evidence through orthotopic lung, brain metastasis, bone metastasis, and systemic dissemination models.
Target Validation & Integrated PK/PD
Programs targeting DLL3, EGFR, MET, TROP2, HER3, HER2, or PD-L1 require confirmation of target status before model selection and verification at endpoint. Alfa Cytology configures target detection and integrated PK/PD workflows based on program needs.
Alfa Cytology is committed to the research and study of cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for lung cancer. If you are interested in our service, please contact us for more information.
References
- Ashrafi, A., et al.; (2022). Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers, 14(19), 4562.
For research use only.
Related Services